China’s gene editing startup YolTech raised $70 million as it accelerates development of CRISPR-based therapies and prepares for a potential Hong Kong IPO. The funding marks the company’s largest round to date and signals continued institutional interest in gene editing platforms despite uneven global clinical outcomes for early CRISPR programs. YolTech’s plan reflects a broader push to translate gene editing into clinic-ready assets, with capital aimed at moving candidates forward through later preclinical and early clinical stages. The company positioned the round as a step toward scaling its therapeutic pipeline. For investors, the round highlights sustained appetite for Chinese gene-editing assets that can reach regulatory milestones quickly under local development timelines.